$13.20 Million in Sales Expected for Neuronetics, Inc. (NASDAQ:STIM) This Quarter

Brokerages expect that Neuronetics, Inc. (NASDAQ:STIMGet Rating) will report $13.20 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Neuronetics’ earnings, with the highest sales estimate coming in at $13.30 million and the lowest estimate coming in at $13.10 million. Neuronetics posted sales of $12.29 million during the same quarter last year, which suggests a positive year-over-year growth rate of 7.4%. The firm is expected to report its next quarterly earnings report before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Neuronetics will report full-year sales of $59.58 million for the current year, with estimates ranging from $58.80 million to $60.36 million. For the next financial year, analysts forecast that the company will report sales of $68.85 million, with estimates ranging from $68.20 million to $69.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Neuronetics.

Neuronetics (NASDAQ:STIMGet Rating) last released its earnings results on Tuesday, March 8th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Neuronetics had a negative return on equity of 33.24% and a negative net margin of 56.39%. The business had revenue of $15.02 million for the quarter, compared to the consensus estimate of $14.67 million. During the same period last year, the business earned ($0.19) earnings per share.

Separately, Zacks Investment Research cut shares of Neuronetics from a “buy” rating to a “hold” rating in a research report on Saturday, March 12th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $10.06.

In related news, major shareholder Cannell Capital Llc purchased 38,786 shares of Neuronetics stock in a transaction on Monday, March 28th. The stock was acquired at an average cost of $2.94 per share, for a total transaction of $114,030.84. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen Furlong sold 10,029 shares of the firm’s stock in a transaction on Wednesday, March 9th. The stock was sold at an average price of $3.00, for a total transaction of $30,087.00. The disclosure for this sale can be found here. In the last quarter, insiders have purchased 147,435 shares of company stock worth $434,119 and have sold 19,929 shares worth $61,635. Company insiders own 5.20% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in STIM. Citigroup Inc. raised its position in Neuronetics by 223.8% in the third quarter. Citigroup Inc. now owns 4,177 shares of the company’s stock worth $27,000 after acquiring an additional 2,887 shares during the period. David J Yvars Group bought a new stake in shares of Neuronetics in the fourth quarter valued at approximately $27,000. BNP Paribas Arbitrage SA increased its holdings in Neuronetics by 469.0% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 5,030 shares of the company’s stock worth $33,000 after acquiring an additional 4,146 shares during the period. Moors & Cabot Inc. bought a new stake in Neuronetics during the 3rd quarter worth approximately $55,000. Finally, Assenagon Asset Management S.A. bought a new stake in Neuronetics during the 1st quarter worth approximately $57,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

NASDAQ STIM opened at $2.50 on Wednesday. Neuronetics has a 1-year low of $2.41 and a 1-year high of $17.92. The firm’s 50 day moving average is $3.04. The company has a quick ratio of 6.93, a current ratio of 7.34 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $66.57 million, a P/E ratio of -2.08 and a beta of 2.31.

Neuronetics Company Profile (Get Rating)

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Featured Stories

Get a free copy of the Zacks research report on Neuronetics (STIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.